Acute myeloid leukemia (AML) is a complex hematological disease characterized by genetic and clinical heterogeneity. Recent advances in the understanding of AML pathogenesis have paved the way for the development of new agents targeting specific molecules or mechanisms that contribute to finally move beyond the current standard of care, which is “3 + 7” regimen. In particular, new therapeutic options such as targeted therapies (midostaurin and enasidenib), monoclonal antibodies (gemtuzumab ozogamicin), and a novel liposomal formulation of cytarabine and daunorubicin (CPX-351) have been recently approved, and will be soon available for the treatment of adult patients with AML. In this review, we will present and describe these recently approved drugs as well as selected novel agents against AML that are currently under investigation, and show the most promising results as monotherapy or in combination with chemotherapy. The selection of these emerging treatments is based on the authors’ opinion.

Novel agents for acute myeloid leukemia / Luppi, Mario; Fabbiano, Francesco; Visani, Giuseppe; Martinelli, Giovanni; Venditti, Adriano. - In: CANCERS. - ISSN 2072-6694. - 10:11(2018), pp. 1-18. [10.3390/cancers10110429]

Novel agents for acute myeloid leukemia

Luppi, Mario;
2018

Abstract

Acute myeloid leukemia (AML) is a complex hematological disease characterized by genetic and clinical heterogeneity. Recent advances in the understanding of AML pathogenesis have paved the way for the development of new agents targeting specific molecules or mechanisms that contribute to finally move beyond the current standard of care, which is “3 + 7” regimen. In particular, new therapeutic options such as targeted therapies (midostaurin and enasidenib), monoclonal antibodies (gemtuzumab ozogamicin), and a novel liposomal formulation of cytarabine and daunorubicin (CPX-351) have been recently approved, and will be soon available for the treatment of adult patients with AML. In this review, we will present and describe these recently approved drugs as well as selected novel agents against AML that are currently under investigation, and show the most promising results as monotherapy or in combination with chemotherapy. The selection of these emerging treatments is based on the authors’ opinion.
2018
10
11
1
18
Novel agents for acute myeloid leukemia / Luppi, Mario; Fabbiano, Francesco; Visani, Giuseppe; Martinelli, Giovanni; Venditti, Adriano. - In: CANCERS. - ISSN 2072-6694. - 10:11(2018), pp. 1-18. [10.3390/cancers10110429]
Luppi, Mario; Fabbiano, Francesco; Visani, Giuseppe; Martinelli, Giovanni; Venditti, Adriano
File in questo prodotto:
File Dimensione Formato  
Luppi_ et al_Cancers basel_Review_2018.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1168599
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact